From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.26
Pain Relevance 0.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (TBXAS1) small molecule metabolic process (TBXAS1) endoplasmic reticulum (TBXAS1)
TBXAS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 2 97.56 Very High Very High Very High
Inflammation 16 97.20 Very High Very High Very High
withdrawal 1 96.28 Very High Very High Very High
COX-2 inhibitor 1 95.40 Very High Very High Very High
aspirin 3 85.64 High High
cINOD 5 85.28 High High
agonist 1 82.92 Quite High
adenocard 5 23.12 Low Low
Kinase C 15 5.00 Very Low Very Low Very Low
Bioavailability 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pain 2 97.56 Very High Very High Very High
INFLAMMATION 21 97.20 Very High Very High Very High
Missed Abortion 1 88.24 High High
Reprotox - General 1 2 86.08 High High
Disease 34 76.28 Quite High
Increased Venous Pressure Under Development 2 75.00 Quite High
Hypertension 2 75.00 Quite High
Hypersensitivity 5 56.28 Quite High
Targeted Disruption 3 49.84 Quite Low
Asthma 6 34.48 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Studies are underway to evaluate the hemodynamic effects of more selective blockers of arachidonate metabolism, such as thromboxane synthase inhibitors and selective inhibitors of PGH synthase-2.
Negative_regulation (inhibitors) of thromboxane synthase
1) Confidence 0.30 Published 1995 Journal Semin. Nephrol. Section Abstract Doc Link 7631051 Disease Relevance 0.35 Pain Relevance 0.29
Since these five synthases, are involved in various important biological processes, they are potential drug targets and drugs are already in the market for the inhibition of PGDS, PGFS, PGIS and TXAS. mPGES-1 is being sought after as a novel target to relieve pain and inflammation after the withdrawal of popular COX-2 inhibitors from the market [8].
Negative_regulation (inhibition) of TXAS associated with pain, inflammation, cox-2 inhibitor and withdrawal
2) Confidence 0.08 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC3009524 Disease Relevance 0.70 Pain Relevance 0.41
For example, SB203580 and PD 98059, in addition to inhibiting p38 and p44/42 MAPKs, have been shown to inhibit the activity of cyclooxygenases and thromboxane synthase [151].
Negative_regulation (inhibit) of thromboxane synthase
3) Confidence 0.07 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733095 Disease Relevance 0.21 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools